Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

PTSD Clinical Trial

Official title:

Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00233467
• Other study ID #: TREAC Retro PTSD
• Status: Withdrawn
• Phase: N/A
• First received: October 3, 2005
• Last updated: September 12, 2017
• Start date: September 1, 2005
• Est. completion date: September 30, 2005

Study information

• Verified date: September 2017
• Source: Tuscaloosa Research & Education Advancement Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main purpose is to show the percentage of patients taking antipsychotics with PTSD by looking at approximately ten year's worth of data from 1994 through 2004. We will also determine the type and dose of antipsychotics the patients received, and to determine how many of those patients had psychotic versus nonpsychotic symptoms. We will be obtaining this data from the VISN 7 Corporate Data Warehouse. We hypothesize that there has been an overall increase in antipsychotic use in patient's with PTSD over the last 10 years.

Description:

This study is a retrospective chart review of patients, at the Tuscaloosa VA Medical Center, who were, treated with antipsychotics as monotherapy or adjunctive therapy.

The data will be retrieved from a computerized list of patients treated at the TVAMC for PTSD from 1994-2004 Charts will be reviewed by looking at approximately ten year's worth of data. Charts will then be examined to determine what type of antipsychotics patients were prescribed, the dose and duration of the antipsychotics, and the presence or absence of documented psychotic symptoms.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 30, 2005
• Est. primary completion date: September 30, 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Have a diagnosis of PTSD (309.81)

2. Male or female patients at least 19 years of age

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Disease
• Posttraumatic Stress Disorder
• PTSD
• Stress Disorders, Post-Traumatic
• Stress Disorders, Traumatic

Locations

Country	Name	City	State
United States	Tuscaloosa VA Medical Center	Tuscaloosa	Alabama

Sponsors (1)

Lead Sponsor	Collaborator
Tuscaloosa Research & Education Advancement Corporation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kozaric-Kovacic D, Pivac N, Mück-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005 Jul;66(7):922-7. — View Citation